A dose dependent reduction in low-density lipoprotein cholesterol (LDL cholesterol) and apolipoprotein B (ApoB) was also observed. Zerlasiran was well tolerated; no clinically important safety concerns were identified. "We are extremely pleased to see the excellent results we saw in healthy volunteers translate to our target population," said Craig Tooman, President and CEO of Silence. "Zerlasiran delivered essentially complete Lp(a) knockdown on repeated dosing with greater durability than seen with single doses. The safety profile also continues to be very well suited for chronic use in a very large global population. We look forward to building on this dataset with the ongoing phase 2 study expected to readout in the first half of next year." Silence plans to present further results from the APOLLO multiple dose study at a future cardiovascular medicines conference.